Zacks Investment Research lowered shares of Proteostasis Therapeutics (NASDAQ:PTI) from a hold rating to a sell rating in a research report report published on Wednesday.

According to Zacks, “Proteostasis Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics to treat diseases caused by an imbalance in the proteostasis network primarily in the United States. Proteostasis Therapeutics, Inc. is based in Cambridge, Massachusetts. “

A number of other equities analysts have also weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Proteostasis Therapeutics in a report on Tuesday, November 6th. They issued a buy rating and a $21.00 price target on the stock. HC Wainwright reiterated a buy rating and issued a $15.00 price target on shares of Proteostasis Therapeutics in a report on Thursday, October 18th. ValuEngine upgraded shares of Proteostasis Therapeutics from a hold rating to a buy rating in a report on Thursday, October 18th. Piper Jaffray Companies assumed coverage on shares of Proteostasis Therapeutics in a report on Monday, October 29th. They issued an overweight rating and a $14.00 price target on the stock. Finally, Royal Bank of Canada upgraded shares of Proteostasis Therapeutics from a sector perform rating to an outperform rating in a report on Thursday, October 18th. Two analysts have rated the stock with a sell rating and six have given a buy rating to the company. The stock has an average rating of Buy and an average target price of $13.86.

PTI stock opened at $4.91 on Wednesday. The company has a market capitalization of $180.55 million, a price-to-earnings ratio of -2.13 and a beta of -3.33. Proteostasis Therapeutics has a one year low of $1.71 and a one year high of $10.38.

Proteostasis Therapeutics (NASDAQ:PTI) last released its earnings results on Tuesday, November 6th. The company reported ($0.50) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.04). The firm had revenue of $1.06 million during the quarter, compared to analysts’ expectations of $0.83 million. Proteostasis Therapeutics had a negative return on equity of 104.17% and a negative net margin of 1,307.84%. As a group, equities analysts anticipate that Proteostasis Therapeutics will post -1.84 earnings per share for the current fiscal year.

In other Proteostasis Therapeutics news, Director Franklin M. Berger bought 40,000 shares of Proteostasis Therapeutics stock in a transaction that occurred on Friday, October 26th. The shares were acquired at an average price of $6.75 per share, for a total transaction of $270,000.00. Following the acquisition, the director now owns 266,162 shares of the company’s stock, valued at approximately $1,796,593.50. The acquisition was disclosed in a filing with the SEC, which is available at this link. Insiders own 19.80% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. Jennison Associates LLC lifted its holdings in shares of Proteostasis Therapeutics by 0.7% during the 3rd quarter. Jennison Associates LLC now owns 3,690,138 shares of the company’s stock valued at $8,893,000 after acquiring an additional 26,428 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Proteostasis Therapeutics by 156.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 46,900 shares of the company’s stock valued at $131,000 after acquiring an additional 28,600 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Proteostasis Therapeutics by 252.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,319 shares of the company’s stock valued at $174,000 after acquiring an additional 44,653 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Proteostasis Therapeutics during the 2nd quarter valued at $141,000. Finally, Bailard Inc. lifted its holdings in shares of Proteostasis Therapeutics by 12.0% during the 2nd quarter. Bailard Inc. now owns 582,400 shares of the company’s stock valued at $1,625,000 after acquiring an additional 62,300 shares in the last quarter. Institutional investors and hedge funds own 63.03% of the company’s stock.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study.

Featured Story: Hedge Funds

Get a free copy of the Zacks research report on Proteostasis Therapeutics (PTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Proteostasis Therapeutics (NASDAQ:PTI)

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.